CovidStanfordV1, Main, Exploration, bibRecord, 000244

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.

Identifieur interne : 000244 ( Main/Exploration ); précédent : 000243; suivant : 000245

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.

Auteurs : Sonali Kochhar [États-Unis] ; Jean-Louis Excler [Corée du Sud] ; Denny Kim [États-Unis] ; James S. Robertson [Royaume-Uni] ; Patricia E. Fast [États-Unis] ; Richard C. Condit [États-Unis] ; Stephen Drew [États-Unis] ; David Wood [Royaume-Uni] ; Marc Gurwith [États-Unis] ; Bettina Klug [Allemagne] ; Mike Whelan [Royaume-Uni] ; Najwa Khuri-Bulos [Jordanie] ; Tamala Mallett Moore [États-Unis] ; Emily R. Smith [États-Unis] ; Robert T. Chen [États-Unis]

Source :

Vaccine [ 1873-2518 ] ; 2020.

RBID : pubmed:32747214

Descripteurs français

KwdFr :
- Agrément de médicaments (législation et jurisprudence), Appréciation des risques (MeSH), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (immunologie), Betacoronavirus (pathogénicité), Coopération internationale (MeSH), Humains (MeSH), Immunogénicité des vaccins (MeSH), Infections à coronavirus (immunologie), Infections à coronavirus (prévention et contrôle), Infections à coronavirus (virologie), Infections à coronavirus (épidémiologie), Pandémies (prévention et contrôle), Pneumopathie virale (immunologie), Pneumopathie virale (prévention et contrôle), Pneumopathie virale (virologie), Pneumopathie virale (épidémiologie), Protection civile (MeSH), Réglementation gouvernementale (MeSH), Sécurité des patients (MeSH), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (biosynthèse), Vaccins antiviraux (normes), Vaccins inactivés (MeSH).
MESH :
- administration et posologie : Vaccins antiviraux.
- biosynthèse : Vaccins antiviraux.
- effets des médicaments et des substances chimiques : Betacoronavirus.
- immunologie : Betacoronavirus, Infections à coronavirus, Pneumopathie virale.
- législation et jurisprudence : Agrément de médicaments.
- normes : Vaccins antiviraux.
- pathogénicité : Betacoronavirus.
- prévention et contrôle : Infections à coronavirus, Pandémies, Pneumopathie virale.
- virologie : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Appréciation des risques, Coopération internationale, Humains, Immunogénicité des vaccins, Protection civile, Réglementation gouvernementale, Sécurité des patients, Vaccins inactivés.

English descriptors

KwdEn :
- Betacoronavirus (drug effects), Betacoronavirus (immunology), Betacoronavirus (pathogenicity), COVID-19 (MeSH), COVID-19 Vaccines (MeSH), Civil Defense (MeSH), Coronavirus Infections (epidemiology), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Coronavirus Infections (virology), Drug Approval (legislation & jurisprudence), Government Regulation (MeSH), Humans (MeSH), Immunogenicity, Vaccine (MeSH), International Cooperation (MeSH), Pandemics (prevention & control), Patient Safety (MeSH), Pneumonia, Viral (epidemiology), Pneumonia, Viral (immunology), Pneumonia, Viral (prevention & control), Pneumonia, Viral (virology), Risk Assessment (MeSH), SARS-CoV-2 (MeSH), Vaccines, Inactivated (MeSH), Viral Vaccines (administration & dosage), Viral Vaccines (biosynthesis), Viral Vaccines (standards).
MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , biosynthesis : Viral Vaccines.
- chemical , standards : Viral Vaccines.
- chemical : COVID-19 Vaccines, Vaccines, Inactivated.
- drug effects : Betacoronavirus.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- immunology : Betacoronavirus, Coronavirus Infections, Pneumonia, Viral.
- legislation & jurisprudence : Drug Approval.
- pathogenicity : Betacoronavirus.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Civil Defense, Government Regulation, Humans, Immunogenicity, Vaccine, International Cooperation, Patient Safety, Risk Assessment, SARS-CoV-2.

Abstract

Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of inactivated viral vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of the vaccine platform. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed inactivated viral vaccines.

DOI: 10.1016/j.vaccine.2020.07.028
PubMed: 32747214
PubMed Central: PMC7834840

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000451
to stream Main, to step Curation: 000451

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.</title>
<author><name sortKey="Kochhar, Sonali" sort="Kochhar, Sonali" uniqKey="Kochhar S" first="Sonali" last="Kochhar">Sonali Kochhar</name>
<affiliation wicri:level="4"><nlm:affiliation>Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
<author><name sortKey="Excler, Jean Louis" sort="Excler, Jean Louis" uniqKey="Excler J" first="Jean-Louis" last="Excler">Jean-Louis Excler</name>
<affiliation wicri:level="3"><nlm:affiliation>International Vaccine Institute, Seoul, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>International Vaccine Institute, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kim, Denny" sort="Kim, Denny" uniqKey="Kim D" first="Denny" last="Kim">Denny Kim</name>
<affiliation wicri:level="2"><nlm:affiliation>Janssen Pharmaceuticals, Titusville, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Pharmaceuticals, Titusville, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Robertson, James S" sort="Robertson, James S" uniqKey="Robertson J" first="James S" last="Robertson">James S. Robertson</name>
<affiliation wicri:level="1"><nlm:affiliation>Independent Adviser, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Independent Adviser</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fast, Patricia E" sort="Fast, Patricia E" uniqKey="Fast P" first="Patricia E" last="Fast">Patricia E. Fast</name>
<affiliation wicri:level="2"><nlm:affiliation>International AIDS Vaccine Initiative, New York, NY, USA; Stanford School of Medicine, Palo Alto, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>International AIDS Vaccine Initiative, New York, NY, USA; Stanford School of Medicine, Palo Alto, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Condit, Richard C" sort="Condit, Richard C" uniqKey="Condit R" first="Richard C" last="Condit">Richard C. Condit</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Drew, Stephen" sort="Drew, Stephen" uniqKey="Drew S" first="Stephen" last="Drew">Stephen Drew</name>
<affiliation wicri:level="1"><nlm:affiliation>Independent Adviser, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Independent Adviser</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wood, David" sort="Wood, David" uniqKey="Wood D" first="David" last="Wood">David Wood</name>
<affiliation wicri:level="1"><nlm:affiliation>Independent Adviser, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Independent Adviser</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gurwith, Marc" sort="Gurwith, Marc" uniqKey="Gurwith M" first="Marc" last="Gurwith">Marc Gurwith</name>
<affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Klug, Bettina" sort="Klug, Bettina" uniqKey="Klug B" first="Bettina" last="Klug">Bettina Klug</name>
<affiliation wicri:level="1"><nlm:affiliation>Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen</wicri:regionArea>
<wicri:noRegion>Langen</wicri:noRegion>
<wicri:noRegion>Langen</wicri:noRegion>
<wicri:noRegion>Langen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Whelan, Mike" sort="Whelan, Mike" uniqKey="Whelan M" first="Mike" last="Whelan">Mike Whelan</name>
<affiliation wicri:level="1"><nlm:affiliation>Project Leader, CEPI, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Project Leader, CEPI</wicri:regionArea>
<wicri:noRegion>CEPI</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Khuri Bulos, Najwa" sort="Khuri Bulos, Najwa" uniqKey="Khuri Bulos N" first="Najwa" last="Khuri-Bulos">Najwa Khuri-Bulos</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Jordan, Amman, Jordan.</nlm:affiliation>
<country xml:lang="fr">Jordanie</country>
<wicri:regionArea>University of Jordan, Amman</wicri:regionArea>
<wicri:noRegion>Amman</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mallett Moore, Tamala" sort="Mallett Moore, Tamala" uniqKey="Mallett Moore T" first="Tamala" last="Mallett Moore">Tamala Mallett Moore</name>
<affiliation wicri:level="2"><nlm:affiliation>Sanofi Pasteur, Swiftwater, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sanofi Pasteur, Swiftwater, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Emily R" sort="Smith, Emily R" uniqKey="Smith E" first="Emily R" last="Smith">Emily R. Smith</name>
<affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chen, Robert T" sort="Chen, Robert T" uniqKey="Chen R" first="Robert T" last="Chen">Robert T. Chen</name>
<affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32747214</idno>
<idno type="pmid">32747214</idno>
<idno type="doi">10.1016/j.vaccine.2020.07.028</idno>
<idno type="pmc">PMC7834840</idno>
<idno type="wicri:Area/Main/Corpus">000451</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000451</idno>
<idno type="wicri:Area/Main/Curation">000451</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000451</idno>
<idno type="wicri:Area/Main/Exploration">000451</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.</title>
<author><name sortKey="Kochhar, Sonali" sort="Kochhar, Sonali" uniqKey="Kochhar S" first="Sonali" last="Kochhar">Sonali Kochhar</name>
<affiliation wicri:level="4"><nlm:affiliation>Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
<author><name sortKey="Excler, Jean Louis" sort="Excler, Jean Louis" uniqKey="Excler J" first="Jean-Louis" last="Excler">Jean-Louis Excler</name>
<affiliation wicri:level="3"><nlm:affiliation>International Vaccine Institute, Seoul, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>International Vaccine Institute, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kim, Denny" sort="Kim, Denny" uniqKey="Kim D" first="Denny" last="Kim">Denny Kim</name>
<affiliation wicri:level="2"><nlm:affiliation>Janssen Pharmaceuticals, Titusville, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Pharmaceuticals, Titusville, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Robertson, James S" sort="Robertson, James S" uniqKey="Robertson J" first="James S" last="Robertson">James S. Robertson</name>
<affiliation wicri:level="1"><nlm:affiliation>Independent Adviser, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Independent Adviser</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fast, Patricia E" sort="Fast, Patricia E" uniqKey="Fast P" first="Patricia E" last="Fast">Patricia E. Fast</name>
<affiliation wicri:level="2"><nlm:affiliation>International AIDS Vaccine Initiative, New York, NY, USA; Stanford School of Medicine, Palo Alto, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>International AIDS Vaccine Initiative, New York, NY, USA; Stanford School of Medicine, Palo Alto, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Condit, Richard C" sort="Condit, Richard C" uniqKey="Condit R" first="Richard C" last="Condit">Richard C. Condit</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Drew, Stephen" sort="Drew, Stephen" uniqKey="Drew S" first="Stephen" last="Drew">Stephen Drew</name>
<affiliation wicri:level="1"><nlm:affiliation>Independent Adviser, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Independent Adviser</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wood, David" sort="Wood, David" uniqKey="Wood D" first="David" last="Wood">David Wood</name>
<affiliation wicri:level="1"><nlm:affiliation>Independent Adviser, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Independent Adviser</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gurwith, Marc" sort="Gurwith, Marc" uniqKey="Gurwith M" first="Marc" last="Gurwith">Marc Gurwith</name>
<affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Klug, Bettina" sort="Klug, Bettina" uniqKey="Klug B" first="Bettina" last="Klug">Bettina Klug</name>
<affiliation wicri:level="1"><nlm:affiliation>Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen</wicri:regionArea>
<wicri:noRegion>Langen</wicri:noRegion>
<wicri:noRegion>Langen</wicri:noRegion>
<wicri:noRegion>Langen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Whelan, Mike" sort="Whelan, Mike" uniqKey="Whelan M" first="Mike" last="Whelan">Mike Whelan</name>
<affiliation wicri:level="1"><nlm:affiliation>Project Leader, CEPI, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Project Leader, CEPI</wicri:regionArea>
<wicri:noRegion>CEPI</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Khuri Bulos, Najwa" sort="Khuri Bulos, Najwa" uniqKey="Khuri Bulos N" first="Najwa" last="Khuri-Bulos">Najwa Khuri-Bulos</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Jordan, Amman, Jordan.</nlm:affiliation>
<country xml:lang="fr">Jordanie</country>
<wicri:regionArea>University of Jordan, Amman</wicri:regionArea>
<wicri:noRegion>Amman</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mallett Moore, Tamala" sort="Mallett Moore, Tamala" uniqKey="Mallett Moore T" first="Tamala" last="Mallett Moore">Tamala Mallett Moore</name>
<affiliation wicri:level="2"><nlm:affiliation>Sanofi Pasteur, Swiftwater, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sanofi Pasteur, Swiftwater, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Emily R" sort="Smith, Emily R" uniqKey="Smith E" first="Emily R" last="Smith">Emily R. Smith</name>
<affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chen, Robert T" sort="Chen, Robert T" uniqKey="Chen R" first="Robert T" last="Chen">Robert T. Chen</name>
<affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (immunology)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>COVID-19 (MeSH)</term>
<term>COVID-19 Vaccines (MeSH)</term>
<term>Civil Defense (MeSH)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Coronavirus Infections (virology)</term>
<term>Drug Approval (legislation & jurisprudence)</term>
<term>Government Regulation (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunogenicity, Vaccine (MeSH)</term>
<term>International Cooperation (MeSH)</term>
<term>Pandemics (prevention & control)</term>
<term>Patient Safety (MeSH)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (prevention & control)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Risk Assessment (MeSH)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Vaccines, Inactivated (MeSH)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (biosynthesis)</term>
<term>Viral Vaccines (standards)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agrément de médicaments (législation et jurisprudence)</term>
<term>Appréciation des risques (MeSH)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (immunologie)</term>
<term>Betacoronavirus (pathogénicité)</term>
<term>Coopération internationale (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Immunogénicité des vaccins (MeSH)</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (prévention et contrôle)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Pandémies (prévention et contrôle)</term>
<term>Pneumopathie virale (immunologie)</term>
<term>Pneumopathie virale (prévention et contrôle)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Protection civile (MeSH)</term>
<term>Réglementation gouvernementale (MeSH)</term>
<term>Sécurité des patients (MeSH)</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (biosynthèse)</term>
<term>Vaccins antiviraux (normes)</term>
<term>Vaccins inactivés (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="standards" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>COVID-19 Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Betacoronavirus</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="legislation & jurisprudence" xml:lang="en"><term>Drug Approval</term>
</keywords>
<keywords scheme="MESH" qualifier="législation et jurisprudence" xml:lang="fr"><term>Agrément de médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pandemics</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pandémies</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Civil Defense</term>
<term>Government Regulation</term>
<term>Humans</term>
<term>Immunogenicity, Vaccine</term>
<term>International Cooperation</term>
<term>Patient Safety</term>
<term>Risk Assessment</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Appréciation des risques</term>
<term>Coopération internationale</term>
<term>Humains</term>
<term>Immunogénicité des vaccins</term>
<term>Protection civile</term>
<term>Réglementation gouvernementale</term>
<term>Sécurité des patients</term>
<term>Vaccins inactivés</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of inactivated viral vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of the vaccine platform. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed inactivated viral vaccines.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32747214</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>38</Volume>
<Issue>39</Issue>
<PubDate><Year>2020</Year>
<Month>09</Month>
<Day>03</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.</ArticleTitle>
<Pagination><MedlinePgn>6184-6189</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0264-410X(20)30944-0</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2020.07.028</ELocationID>
<Abstract><AbstractText>Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of inactivated viral vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of the vaccine platform. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed inactivated viral vaccines.</AbstractText>
<CopyrightInformation>Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kochhar</LastName>
<ForeName>Sonali</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Excler</LastName>
<ForeName>Jean-Louis</ForeName>
<Initials>JL</Initials>
<AffiliationInfo><Affiliation>International Vaccine Institute, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Denny</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Janssen Pharmaceuticals, Titusville, NJ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Robertson</LastName>
<ForeName>James S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo><Affiliation>Independent Adviser, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fast</LastName>
<ForeName>Patricia E</ForeName>
<Initials>PE</Initials>
<AffiliationInfo><Affiliation>International AIDS Vaccine Initiative, New York, NY, USA; Stanford School of Medicine, Palo Alto, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Condit</LastName>
<ForeName>Richard C</ForeName>
<Initials>RC</Initials>
<AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Drew</LastName>
<ForeName>Stephen</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Independent Adviser, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wood</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Independent Adviser, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gurwith</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Klug</LastName>
<ForeName>Bettina</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Whelan</LastName>
<ForeName>Mike</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Project Leader, CEPI, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Khuri-Bulos</LastName>
<ForeName>Najwa</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>University of Jordan, Amman, Jordan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mallett Moore</LastName>
<ForeName>Tamala</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Sanofi Pasteur, Swiftwater, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Smith</LastName>
<ForeName>Emily R</ForeName>
<Initials>ER</Initials>
<AffiliationInfo><Affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Robert T</ForeName>
<Initials>RT</Initials>
<AffiliationInfo><Affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Electronic address: brightoncollaborationv3swg@gmail.com</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002959" MajorTopicYN="N">Civil Defense</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>
<QualifierName UI="Q000331" MajorTopicYN="Y">legislation & jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D033161" MajorTopicYN="N">Government Regulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007391" MajorTopicYN="N">International Cooperation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061214" MajorTopicYN="N">Patient Safety</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018570" MajorTopicYN="Y">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
<QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Benefit-risk</Keyword>
<Keyword MajorTopicYN="Y">Brighton Collaboration</Keyword>
<Keyword MajorTopicYN="Y">CEPI</Keyword>
<Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">Inactivated</Keyword>
<Keyword MajorTopicYN="Y">Safety</Keyword>
<Keyword MajorTopicYN="Y">Template</Keyword>
<Keyword MajorTopicYN="Y">Vaccine</Keyword>
<Keyword MajorTopicYN="Y">Virus</Keyword>
</KeywordList>
<CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>07</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>07</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32747214</ArticleId>
<ArticleId IdType="pii">S0264-410X(20)30944-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2020.07.028</ArticleId>
<ArticleId IdType="pmc">PMC7834840</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Semin Immunol. 2018 Oct;39:14-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29801750</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2017 Sep;16(9):883-894</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28724343</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Jan 1;33(1):62-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25446819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Jan 1;33(1):73-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25305565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 May 29;368(6494):945-946</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32385100</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Dec 12;34(51):6597-6609</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27395563</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2012 Jun;11(6):695-719</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22873127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2020 Nov 6;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33168344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2002 Dec 13;21(3-4):298-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12450705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2020 May;19(5):305-306</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32273591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine X. 2019 Jan 29;1:100009</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31384731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Apr 6;27(16):2282-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19056451</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Corée du Sud</li>
<li>Jordanie</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Floride</li>
<li>Géorgie (États-Unis)</li>
<li>New Jersey</li>
<li>Pennsylvanie</li>
<li>Région capitale de Séoul</li>
<li>Washington (État)</li>
</region>
<settlement><li>Seattle</li>
<li>Séoul</li>
</settlement>
<orgName><li>Université de Washington</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Washington (État)"><name sortKey="Kochhar, Sonali" sort="Kochhar, Sonali" uniqKey="Kochhar S" first="Sonali" last="Kochhar">Sonali Kochhar</name>
</region>
<name sortKey="Chen, Robert T" sort="Chen, Robert T" uniqKey="Chen R" first="Robert T" last="Chen">Robert T. Chen</name>
<name sortKey="Condit, Richard C" sort="Condit, Richard C" uniqKey="Condit R" first="Richard C" last="Condit">Richard C. Condit</name>
<name sortKey="Drew, Stephen" sort="Drew, Stephen" uniqKey="Drew S" first="Stephen" last="Drew">Stephen Drew</name>
<name sortKey="Fast, Patricia E" sort="Fast, Patricia E" uniqKey="Fast P" first="Patricia E" last="Fast">Patricia E. Fast</name>
<name sortKey="Gurwith, Marc" sort="Gurwith, Marc" uniqKey="Gurwith M" first="Marc" last="Gurwith">Marc Gurwith</name>
<name sortKey="Kim, Denny" sort="Kim, Denny" uniqKey="Kim D" first="Denny" last="Kim">Denny Kim</name>
<name sortKey="Mallett Moore, Tamala" sort="Mallett Moore, Tamala" uniqKey="Mallett Moore T" first="Tamala" last="Mallett Moore">Tamala Mallett Moore</name>
<name sortKey="Smith, Emily R" sort="Smith, Emily R" uniqKey="Smith E" first="Emily R" last="Smith">Emily R. Smith</name>
</country>
<country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Excler, Jean Louis" sort="Excler, Jean Louis" uniqKey="Excler J" first="Jean-Louis" last="Excler">Jean-Louis Excler</name>
</region>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Robertson, James S" sort="Robertson, James S" uniqKey="Robertson J" first="James S" last="Robertson">James S. Robertson</name>
</noRegion>
<name sortKey="Whelan, Mike" sort="Whelan, Mike" uniqKey="Whelan M" first="Mike" last="Whelan">Mike Whelan</name>
<name sortKey="Wood, David" sort="Wood, David" uniqKey="Wood D" first="David" last="Wood">David Wood</name>
</country>
<country name="Allemagne"><noRegion><name sortKey="Klug, Bettina" sort="Klug, Bettina" uniqKey="Klug B" first="Bettina" last="Klug">Bettina Klug</name>
</noRegion>
</country>
<country name="Jordanie"><noRegion><name sortKey="Khuri Bulos, Najwa" sort="Khuri Bulos, Najwa" uniqKey="Khuri Bulos N" first="Najwa" last="Khuri-Bulos">Najwa Khuri-Bulos</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000244 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000244 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidStanfordV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32747214
   |texte=   The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32747214" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidStanfordV1

This area was generated with Dilib version V0.6.38.
Data generation: Tue Feb 2 21:24:25 2021. Site generation: Tue Feb 2 21:26:08 2021

	Serveur d'exploration sur le Covid à Stanford
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le Covid à Stanford

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki